How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Human Vaccine Adjuvants Market
- By Adjuvant Type: Aluminum Salts (Alum), Oil-in-Water Emulsions, Toll-Like Receptor (TLR) Agonists, Saponin-Based Adjuvants, Liposomes, Cytokines
- By Vaccine Type: Inactivated Vaccines, Live Attenuated Vaccines, Subunit Vaccines, Conjugate Vaccines, mRNA Vaccines, Viral Vector Vaccines
- By Application: Prophylactic Vaccines, Therapeutic Vaccines
- By End-User: Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Academic and Research Institutes
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Aluminum Salts (Alum) leads By Adjuvant Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 275 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.164 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.172 →
Full report · locked preview
Everything inside the Human Vaccine Adjuvants Market report
A complete, evidence-based study - 11 chapters and 115 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Adjuvant Type 6
Vaccine Type 6
Application 2
End-User 3
Companies profiled
GlaxoSmithKline plc
Dynavax Technologies Corporation
Novavax Inc.
Sanofi S.A.
BASF SE
Becton
Dickinson and Company (BD)
Croda International Plc
Lonza Group AG
Seppic (Air Liquide)
Evonik Industries AG
Vaxine Pty Ltd
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →GlaxoSmithKline plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Dynavax Technologies Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Novavax Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Sanofi S.A.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →BASF SE
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Becton
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Dickinson and Company (BD)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Croda International Plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Lonza Group AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Seppic (Air Liquide)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Evonik Industries AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Vaxine Pty Ltd
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Valneva SE
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Biondvax Pharmaceuticals Ltd
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Adjuvance Technologies
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,634M by 2033 · 11.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Aluminum Salts (Alum)40.2
- Oil-in-Water Emulsions11.7
- Toll-Like Receptor (TLR) Agonists14.6
- Saponin-Based Adjuvants11.5
- Liposomes10.7
- Cytokines11.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$225.5M → $600.1M · 13.0%
Europe$157.2M → $385.7M · 11.9%
Asia Pacific$143.5M → $332.9M · 11.1%
Latin America$88.8M → $195.6M · 10.4%
Middle East and Africa$68.3M → $183.1M · 13.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.462026
11.472027
11.482028
11.492029
11.512030
11.532031
11.542032
11.552033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- GlaxoSmithKline plc16.9
- Dynavax Technologies Corporation22.3
- Novavax Inc.7.2
- Sanofi S.A.8.1
- BASF SE10.7
- Becton6.7
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Adjuvant Type17.8%
Vaccine Type34.0%
Application32.6%
End-User15.6%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.4
- Europe22.7
- Asia Pacific19.6
- Latin America11.5
- Middle East and Africa10.8
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| GlaxoSmithKline plc | 86 | 90 | 95 | 99 | 95 | 75 | 90 |
| Dynavax Technologies Corporation | 75 | 79 | 88 | 70 | 83 | 75 | 78 |
| Novavax Inc. | 88 | 81 | 85 | 67 | 68 | 71 | 77 |
| Sanofi S.A. | 70 | 67 | 59 | 66 | 72 | 68 | 67 |
| BASF SE | 74 | 67 | 71 | 69 | 73 | 76 | 72 |
| Becton | 54 | 57 | 62 | 48 | 66 | 69 | 59 |
| Dickinson and Company (BD) | 62 | 65 | 66 | 62 | 63 | 63 | 64 |
| Croda International Plc | 40 | 57 | 41 | 45 | 49 | 42 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- GlaxoSmithKline plc
- Dynavax Technologies Corporation
- Novavax Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| GlaxoSmithKline plc | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Dynavax Technologies Corporation | ◐ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Novavax Inc. | ✓ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Sanofi S.A. | ✓ | ✓ | ◐ | ◐ | ✓ | ◐ |
| BASF SE | ◐ | − | ✓ | ✓ | − | ◐ |
| Becton | − | − | ◐ | − | ◐ | − |
| Dickinson and Company (BD) | ◐ | ◐ | ✓ | ✓ | − | − |
| Croda International Plc | − | − | − | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1GlaxoSmithKline plc90
2Dynavax Technologies Corporation78
3Novavax Inc.77
4BASF SE72
5Sanofi S.A.67
6Dickinson and Company (BD)64
7Becton59
8Croda International Plc46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
GlaxoSmithKline plcDynavax Technologies Corporation
Challenger3
Strong scale, closing on the leaders.
Novavax Inc.Sanofi S.A.BASF SE
Contender2
Focused players with pockets of strength.
BectonDickinson and Company (BD)
Niche1
Specialists in a single segment or region.
Croda International Plc
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Adjuvant Type in North America, then scale across Human Vaccine Adjuvants Market — a $365M beachhead inside a $5.47B market.
Beachhead (SOM)$365Mobtainable near-term
Serviceable (SAM)$2.22Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Aluminum Salts (Alum)
Best fit — highest urgency & budget in Adjuvant Type.
Economic buyer79 fit
Oil-in-Water Emulsions
Strong fit — clear ROI and a fast path to value.
End user64 fit
Toll-Like Receptor (TLR) Agonists
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Adjuvant Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Vaccine Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel27%
Digital / self-serve20%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Adjuvant Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Human Vaccine Adjuvants Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified21%
Evaluation14%
Closed-won7%
$17.2KCAC
$71KLTV
4.1:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Human Vaccine Adjuvants Market is a high-growth opportunity — $4.13B by 2033, compounding at 10.1%.
TAM · 2025$1.91Btoday
TAM · 2033$4.13Bforecast
CAGR10.1%2027–2033
Cumulative$26.1Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.13BTotal addressable market
SAM$1.59BServiceable available market
SOM$268MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.1% CAGR
Demand compounds through 2033, outpacing GDP across Adjuvant Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Adjuvant Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.13BLarge & growingTAM by 2033 at 10.1% CAGR
$1.59BServiceable nowreachable with today’s model
$268MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.22BBear6.6% CAGR
$4.13BBase10.1% CAGR
$5.29BBull13.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Vaccine Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Human Vaccine Adjuvants Market — a $5.41B market by 2033. Plan: grow share from 10.3% to 17.3%.
Market size · 2033$5.41Btotal addressable
Market CAGR7.2%2027–2033
Target share17.3%from 10.3% today
Revenue ambition$935Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.3% | 17.3% | At risk |
| Revenue | $506M | $935M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 32.5% | 43.5% | Ahead |
| Customer retention | 91.1% | 94.3% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Adjuvant Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Vaccine Type capability
A defensible second engine — invest in Vaccine Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Adjuvant Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Vaccine Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $96M capacity & capability investment
- Greenlight bolt-on M&A in Vaccine Type
- Authorise North America expansion plan
- Fund R&D program for Adjuvant Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Human Vaccine Adjuvants Market conversation — a $7.82B market you can size, segment and defend in minutes.
Market size · 2033$7.82Btotal opportunity
Growth9.8%CAGR to 2033
Addressable buyers1,697+accounts in scope
Typical ROI4.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Adjuvant Type
Goal Grow share in Adjuvant Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.9×return on cost, year one
< 2 mopayback period
$46K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
GlaxoSmithKline plcDynavax Technologies CorporationNovavax Inc.Sanofi S.A.BASF SEBectonDickinson and Company (BD)Croda International Plc+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Human Vaccine Adjuvants Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Human Vaccine Adjuvants Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Varicella Virus Vaccine Live Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportSimply Drug Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportParicalcitol Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportSomatuline Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportIntracranial Shunt Device Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportLanreotide Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportOrencia abatacept Drug Market
Market size, share, segmentation and regional forecast.
$344M market · 2025 base year
View reportSulbenicillin Sodium Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportAlibendol Market
Market size, share, segmentation and regional forecast.
$918M market · 2025 base year
View reportPorcine Circovirus Vaccine Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportDrugs for Dermatophytosis Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportPorcine Reproductive Respiratory Syndrome PRRS Vaccines Market
Market size, share, segmentation and regional forecast.
$675M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.